VanEck Associates
BEAM icon

VanEck Associates’s Beam Therapeutics BEAM Stock Holding History

VanEck Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,884
Closed -$69K – 1344
2026
Q1 		$69K Sell
2,884
-1,035
-26% -$28.7K ﹤0.01% 1322
2025
Q4 		$109K Buy
3,919
+1,761
+82% +$44.9K ﹤0.01% 1319
2025
Q3 		$52K Buy
2,158
+707
+49% +$14.1K ﹤0.01% 1343
2025
Q2 		$25K Buy
1,451
+147
+11% +$2.56K ﹤0.01% 1348
2025
Q1 		$25K Buy
1,304
+316
+32% +$8.28K ﹤0.01% 1330
2024
Q4 		$25K Buy
988
+138
+16% +$3.52K ﹤0.01% 1329
2024
Q3 		$19K Sell
850
-190
-18% -$4.91K ﹤0.01% 1315
2024
Q2 		$24K Sell
1,040
-105
-9% -$2.58K ﹤0.01% 1320
2024
Q1 		$38K Hold
1,145
– – ﹤0.01% 1293
2023
Q4 		$31K Buy
1,145
+57
+5% +$1.42K ﹤0.01% 1310
2023
Q3 		$26K Hold
1,088
– – ﹤0.01% 1323
2023
Q2 		$35K Hold
1,088
– – ﹤0.01% 1320
2023
Q1 		$33K Sell
1,088
-36
-3% -$1.42K ﹤0.01% 1332
2022
Q4 		$44K Buy
1,124
+408
+57% +$18.3K ﹤0.01% 1322
2022
Q3 		$34K Buy
+716
New +$40.8K ﹤0.01% 1291

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

VanEck Associates's BEAM Position: Q2 2026 in Review

VanEck Associates sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 2,884 shares — an estimated $69K sold.

VanEck Associates first reported a position in BEAM in Q3 2022 and held it in 15 quarters. The position peaked at $109K in Q4 2025. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • VanEck Associates reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 2,884 Beam Therapeutics shares in Q2 2026, an estimated $69K.
  • VanEck Associates first reported a position in Beam Therapeutics in Q3 2022 and held it in 15 quarters.
  • VanEck Associates's Beam Therapeutics position peaked at $109K in Q4 2025.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.